Clinical ResearchAcute Coronary SyndromePrognostic Significance of Periprocedural Versus Spontaneously Occurring Myocardial Infarction After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes: An Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Key Words
Abbreviations and Acronyms
Cited by (0)
The ACUITY trial was funded by The Medicines Company (Parsippany, New Jersey) and Nycomed (Roskilde, Denmark). Dr. Gersh is a consultant to and/or member of the Data Safety Monitoring Board for AstraZeneca, Bristol-Myers Squibb, Abbott Laboratories, and Boston Scientific and is a shareholder of CV Therapeutics. Dr. Lincoff has received research grants from The Medicines Company and Sanofi-Aventis. Dr. Ohman is a consultant for CV Therapeutics, Northpoint Domain, Pozen, WebMD, The Medicines Company, Inovise, Liposcience, Response Biomedical, Datascope, and Abioed; is a recipient of research grants from AstraZeneca, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo, Datascope, Eli Lilly, Sanofi-Aventis, Schering-Plough, and The Medicines Company; and is a shareholder of Inovise. For a complete listing including institutional disclosures, go to www.dcri.duke.edu/research/coi.jsp. Dr. White has received research grants from Sanofi-Aventis, Eli Lilly, The Medicines Company, National Institutes of Health, Pfizer, Roche, Johnson & Johnson, Schering-Plough, Merck Sharpe & Dohme, AstraZeneca, GlaxoSmithKline, and Daiichi Sankyo Pharma Development, and consulting fees from GlaxoSmithKline and Sanofi-Aventis. Dr. Pocock has received consulting fees from The Medicines Company. Dr. Cox is a member of the Speakers' Bureau of The Medicines Company. Dr. Mehran has been a consultant with Abbott and has received speaking honoraria from The Medicines Company, Lily/Daiichi Sankyo, Medtronic Vascular, Boston Scientific, Cordis Corp., and Sanofi-Aventis. Dr. Stone has received research grants from The Medicines Company, Boston Scientific, and Abbott Vascular.